CMPS is trading 5% up at $13.64 as the stock rebounds from a sharp selloff tied to investor reaction to six-month durability results from its COMP006 Phase 3 trial in treatment-resistant depression.
- The move comes as the market continues to digest data that showed rapid, durable efficacy and a generally well-tolerated safety profile.
- Investors are stepping back into the stock after the initial drop, reassessing the clinical data following the recent volatility.